Cargando…

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review

BACKGROUND: Triple negative breast cancer (TNBC) represents 15–20% of breast cancers. Due to its heterogeneity and high rates of relapse, there is a need to optimize treatment efficacy. Platinum chemotherapy is still controversial and currently not recommended as first-line treatment for TNBC. Recen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandy, Jessa Gilda P., Balolong-Garcia, Joanmarie C., Cruz-Ordinario, Mel Valerie B., Que, Frances Victoria F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839096/ https://www.ncbi.nlm.nih.gov/pubmed/31703646 http://dx.doi.org/10.1186/s12885-019-6253-5

Ejemplares similares

Risk factors and clinical outcomes of systemic cancer treatment delays in Filipino patients with solid tumor malignancy during the COVID‐19 pandemic: A single tertiary center study
por: Pandy, Jessa Gilda, et al.
Publicado: (2021)

MO33-3 Clinical characteristics and outcomes of cancer patients with COVID-19: A study in a single center in the Philippines
por: Gilda P Pandy, Jessa, et al.
Publicado: (2021)

Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis
por: Lin, Canling, et al.
Publicado: (2022)

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
por: LIU, MIAO, et al.
Publicado: (2013)

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2020)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis
por: Kaya, Vildan, et al.
Publicado: (2018)

Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis
por: Li, Junjie, et al.
Publicado: (2022)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer
por: Jia, Xiaomeng, et al.
Publicado: (2022)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
por: He, Qin, et al.
Publicado: (2021)

A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer
por: Feng, Wuna, et al.
Publicado: (2021)

Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials
por: Xie, Kaigang, et al.
Publicado: (2022)

Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials
por: Bian, Lei, et al.
Publicado: (2021)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis
por: Zhang, Liulu, et al.
Publicado: (2022)

Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis
por: Sandhu, Gurprataap S., et al.
Publicado: (2016)

Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy
por: Walsh, Elaine M., et al.
Publicado: (2018)

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients
por: Wang, Biyun, et al.
Publicado: (2022)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis
por: Hercules, Shawn M, et al.
Publicado: (2022)

Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Fei, et al.
Publicado: (2021)

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression
por: KHALAF, DANIEL, et al.
Publicado: (2014)

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers
por: Birkbak, N J, et al.
Publicado: (2018)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis
por: Clark, Otávio, et al.
Publicado: (2014)

MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis
por: Lü, Lingshuang, et al.
Publicado: (2017)

Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis
por: Harborg, Sixten, et al.
Publicado: (2021)

Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis
por: Lin, Ying-Yi, et al.
Publicado: (2022)

The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer
por: Vernieri, Claudio, et al.
Publicado: (2018)

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
por: Lips, Esther H., et al.
Publicado: (2020)

Update on systemic treatment in early triple negative breast cancer
por: Núñez Abad, Martín, et al.
Publicado: (2021)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3gqcmo1k2j080b6hsbq0tt0383